Sumitomo Pharma Co., Ltd. (DNPUF)
OTCMKTS · Delayed Price · Currency is USD
10.99
0.00 (0.00%)
At close: Oct 29, 2025
Sumitomo Pharma Revenue
Sumitomo Pharma had revenue of 119.12B JPY in the quarter ending September 30, 2025, with 32.25% growth. This brings the company's revenue in the last twelve months to 445.21B, up 29.92% year-over-year. In the fiscal year ending March 31, 2025, Sumitomo Pharma had annual revenue of 398.83B with 26.79% growth.
Revenue (ttm)
445.21B JPY
Revenue Growth
+29.92%
P/S Ratio
1.51
Revenue / Employee
116.18M JPY
Employees
3,832
Market Cap
4.34B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 398.83B | 84.27B | 26.79% |
| Mar 31, 2024 | 314.56B | -240.99B | -43.38% |
| Mar 31, 2023 | 555.54B | -4.49B | -0.80% |
| Mar 31, 2022 | 560.04B | 44.08B | 8.54% |
| Mar 31, 2021 | 515.95B | 33.22B | 6.88% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |